Our Theranostic technology and approach has been featured in the following publications
2016-present
2024
Bauer D, Carter LM, Atmane M, Gregorio RD, Michel A, Kaminsky S, Monette S, Li M, Schultz MK, Lewis JS. 212Pb-Pretargeted Theranostics for Pancreatic Cancer. Journal of Nuclear Medicine; 2024, 65(1):109-116.
Graves S, Li M, Lee D, & Schultz MK. On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer. In: Prasad, V. (eds) Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer, Cham. 2024, pp 277–287.
Gape PMD, Schultz MK, Stasiuk GJ, Terry SYA. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review. Pharmaceuticals; 2024, 17(3):334.
Thakral P, Sen IB, Das SS, Schultz MK, Kumari J, Virupakshappa CB, Malik D. Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent. Indian Journal of Nuclear Medicine; 2024, 39(2):142-143.
Singh N, Rana N, Thakral P, Malik D, Schultz MK, Sen IB. Charting the Course of Targeted α Therapy with First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors. Clinical Nuclear Medicine; 2024, 49(6):546-548.
Li M, Robles-Planells C, Liu D, Graves SA, Vasquez-Martinez G, Mayoral-Andrade G, Lee D, Rastogi P, Marks BM, Sagastume EA, Weiss RM, Linn-Peirano SC, Johnson FL, Schultz MK, Zepeda-Orozco DZ. Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging; 2024, 51(5):1395-1408.
2023
Saini S, Bartels J, Appiah JPK, Rider JH, Baumhover N, Schultz MK, Lapi SE. Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets. Journal of Nuclear Medicine; 2023, 64(11):1791-1797.
Pretze M, Michler E, Runge R, Wetzig K, Tietze K, Brandt F, Schultz MK, Kotzerke J. Influence of the Molar Activity of 203/212Pb-PSC-PEG2-TOC on Somatostatin Receptor Type 2-Binding and Cell Uptake. Pharmaceuticals (Basel); 2023, 16(11):1605.
Michler E, Kästner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, Schultz MK, Kotzerke J. First-in-human SPECT/CT imaging of [212Pb]Pb-VMT-α-NET in a patient with metastatic neuroendocrine tumor. European Journal of Nuclear Medicine; 2023, (5):1490-1492.
Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, Rastogi P, Pigge FC, Menda Y, Johnson FL, Schultz MK. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. European Journal of Nuclear Medicine; 2023, 51(4):1147-1162.
Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, Lee D, Dai Z, Obot ER, Marks BM, Okeil I, Sagastume EA, Gabr M, Pigge FC, Johnson FL, Schultz MK. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics. Pharmaceutics, 2023, (15), 414.
Nelson BJB, Wilson J, Schultz MK, Andersson JD, Wuest F. High-yield cyclotron production of 203Pb using a sealed 205Tl solid target. Nuclear Medicine and Biology, 2023, (116-117), 108314.
Mueller D, Herrmann H, Schultz MK, Solbach C, Ettrich T, Prasad V. [203Pb]VMT-α-NET Scintigraphy of a patient with neuroendocrine tumor. Clinical Nuclear Medicine, 2023, (48), 54-55.
2022
Orcutt KD, Henry KE, Habjan C, Palmer K, Heimann J, Cupido JM, Gottumukkala V, Cissell DD, Lyon M, Hussein AI, Liu D, Li M, Johnson FL, & Schultz MK. Dosimetry of [212Pb]VMT01, a MC1R-targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses. Molecules, 2022, 27(18):5831.
Schultz MK, Pouget JP, Wuest F, Nelson B, Andersson J, Cheal S et al. Radiobiology of Targeted Alpha Therapy. In Nuclear Medicine and Molecular Imaging: Volume 1-4, 2022, 4:380-403.
2021
Kunos CA, Mankoff DA, Schultz MK, Graves SA, Pryma DA. Radiopharmaceutical Chemistry and Drug Development - What's Changed? Seminars in Radiation Oncology, 2021, 31(1):3-11.
Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, Sagastume EA, Ballas ZK, Johnson FL, Morris ZS, Schultz MK. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, 13(15):3676.
2020
Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves SA, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, and Schultz MK. Pb-203/Pb-212 Theranostic Radiopharmaceuticals for Image-Guided Radionuclide Therapy for Cancer. Current Medicinal Chemistry, 2020, 27(1):1-29.
2019
Li M, Lee D, Liu D, Quinn TP, Sagastume EA, Mott S, Gibsen-Corley KN, Johnson FL, Schultz MK. MAPK and HDAC Inhibitors Sensitize Malignant Melanoma to Alpha-particle Radiation Targeting Melanocortin Subtype 1 Receptor (MC1R). Molecular Pharmaceutics, 2019, 16(9):3904-3915.
2018
Menda Y, Madsen MT, O'Dorisio TM, Sunderland J, Watkins LG, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2018, 59(11):1692-1698.
Lee D, Li M, Bednarz B, Schultz MK. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiation Research, 2018, 190(3):236-247.
Ghai A, Singh B, Li M, Daniels TA, Coelho R, Orcutt K, Watkins GL, Norenberg JP, Cvet D, Schultz MK. Optimizing the Radiosynthesis of [68Ga]DOTA-MLN6907 Peptide Containing Three Disulfide Cyclization Bonds - A GCC Specific Chelate for Clinical Radiopharmaceuticals. Applied Radiation and Isotopes, 2018, 140:333-341.
2017
Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, Zimmerman BE, McAlister D, Olewine K, Menda Y, Mirzadeh S, Copping R, Sagastume, Johnson FL, Schultz MK. Production of High Specific Activity [203/212-Pb]DOTA-Conjugated Radiopharmaceuticals for Clinical Image-Guided Radionuclide Cancer Therapy Using an Automated Cassette-Based System. Applied Radiation and Isotopes, 2017, 127:52-60.
May D, Nelson AN, Schultz MK. Quantitation of Lead-210 (Pb-210) Using Lead-203 (Pb-203) as a 'Massless' Yield Tracer. Journal of Environmental Radioactivity, 2017, 171:93-98.